ERBB2 and triple-negative breast carcinoma: Of the patients participating in the study, 82.2% (n = 897) were positive for hormone receptor + (HR+), 16.1% (n = 176) for c-erb-B2 (HER2-neu), and 7.6% (n = 83) of the patients were diagnosed with triple-negative breast cancer.